Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults with Philadelphia chromosome-positive chronic phase chronic myeloid leukemia after at least two tyrosine kinase inhibitors.
LAMPGEN ANALYSIS
Why it matters
The initial accelerated action added an allosteric BCR::ABL1 inhibitor after two prior TKIs. FDA granted traditional approval on October 12, 2022.
What research teams should watch
Record previous TKIs and why each was discontinued and distinguish the separate T315I indication.
PRIMARY RECORDS